Christopher Raymond
Stock Analyst at Raymond James
Total Price Targets
39
Stocks Covered
16
Sectors
Healthcare
Most Recent
Mar 10, 2026
Notable Calls (Last 12 Months)
Most Bullish
Stocks Covered by Christopher Raymond
| Symbol | Company | Latest Target | Current Price | Upside | # Targets | Last Updated |
|---|---|---|---|---|---|---|
| CLYM | Climb Bio, Inc. | $25.00 | $8.97 | +178.7% | 1 | Mar 10, 2026 |
| ALMS | Alumis Inc. Common Stock | $46.00 | $25.27 | +82.0% | 1 | Mar 10, 2026 |
| ARDX | Ardelyx, Inc. | $19.00 | $6.93 | +174.0% | 2 | Jan 8, 2026 |
| REGN | Regeneron Pharmaceuticals, Inc. | $723.00 | $703.72 | +2.7% | 6 | Oct 28, 2025 |
| BIIB | Biogen Inc. | $315.00 | $186.69 | +68.7% | 5 | Oct 30, 2024 |
| AMGN | Amgen Inc. | $344.00 | $328.69 | +4.7% | 3 | Sep 25, 2024 |
| NUVL | Nuvalent, Inc. | $100.00 | $99.45 | +0.5% | 1 | Sep 16, 2024 |
| BMRN | BioMarin Pharmaceutical Inc. | $122.00 | $54.20 | +125.1% | 3 | Sep 5, 2024 |
| ABBV | AbbVie Inc. | $209.00 | $206.29 | +1.3% | 4 | Aug 23, 2024 |
| TYRA | Tyra Biosciences, Inc. | $33.00 | $34.09 | -3.2% | 1 | Aug 15, 2024 |
| TSHA | Taysha Gene Therapies, Inc. | $7.00 | $6.38 | +9.7% | 2 | Jul 1, 2024 |
| ALXO | ALX Oncology Holdings Inc. | $21.00 | $1.70 | +1135.3% | 1 | Jun 3, 2024 |
| RARE | Ultragenyx Pharmaceutical Inc. | $135.00 | $24.79 | +444.7% | 5 | May 31, 2024 |
| VRTX | Vertex Pharmaceuticals Incorporated | $456.00 | $425.06 | +7.3% | 1 | May 7, 2024 |
| SLDB | Solid Biosciences Inc. | $20.00 | $7.14 | +179.9% | 1 | Mar 13, 2024 |
| CALC | CalciMedica, Inc. | $392.00 | $0.60 | +65760.2% | 2 | Nov 22, 2022 |
Recent Activity
- Mar 10, 2026— Set$46.00price target onALMS(Alumis Inc. Common Stock)
- Mar 10, 2026— Set$25.00price target onCLYM(Climb Bio, Inc.)
- Jan 8, 2026— Set$19.00price target onARDX(Ardelyx, Inc.)
- Oct 28, 2025— Set$723.00price target onREGN(Regeneron Pharmaceuticals, Inc.)
- Sep 2, 2025— Set$673.00price target onREGN(Regeneron Pharmaceuticals, Inc.)
- Nov 1, 2024— Set$1195.00price target onREGN(Regeneron Pharmaceuticals, Inc.)
- Oct 30, 2024— Set$315.00price target onBIIB(Biogen Inc.)
- Sep 25, 2024— Set$344.00price target onAMGN(Amgen Inc.)
- Sep 16, 2024— Set$100.00price target onNUVL(Nuvalent, Inc.)
- Sep 5, 2024— Set$122.00price target onBMRN(BioMarin Pharmaceutical Inc.)
- Aug 27, 2024— Set$107.00price target onBMRN(BioMarin Pharmaceutical Inc.)
- Aug 23, 2024— Set$209.00price target onABBV(AbbVie Inc.)
- Aug 23, 2024— Set$1242.00price target onREGN(Regeneron Pharmaceuticals, Inc.)
- Aug 15, 2024— Set$33.00price target onTYRA(Tyra Biosciences, Inc.)
- Jul 26, 2024— Set$307.00price target onBIIB(Biogen Inc.)
- Jul 19, 2024— Set$1166.00price target onREGN(Regeneron Pharmaceuticals, Inc.)
- Jul 12, 2024— Set$313.00price target onBIIB(Biogen Inc.)
- Jul 1, 2024— Set$7.00price target onTSHA(Taysha Gene Therapies, Inc.)
- Jun 18, 2024— Set$190.00price target onABBV(AbbVie Inc.)
- Jun 3, 2024— Set$21.00price target onALXO(ALX Oncology Holdings Inc.)
Frequently Asked Questions
Who is Christopher Raymond?
Christopher Raymond is a stock analyst at Raymond James covering 16 stocks primarily in Healthcare. They have issued 39 price targets since Sep 27, 2021.
What stocks does Christopher Raymond cover?
Christopher Raymond currently covers 16 stocks, including REGN, BIIB, RARE, ABBV, AMGN.
What is Christopher Raymond's latest price target?
Christopher Raymond's most recent price target was $46.00 on ALMS (Alumis Inc. Common Stock), set on Mar 10, 2026.
What is Christopher Raymond's highest price target?
Christopher Raymond's highest issued price target is $1242.00 on REGN, set on Aug 23, 2024.
More Analysts at Raymond James
Coverage based on publicly published price targets. Not investment advice.